Trial Search Results

Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor

The purpose of this trial is to study how well modafinil works in treating children with memory and attention problems caused by cancer treatment for a brain tumor. Modafinil may help improve memory, attention, and fatigue caused by cancer treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

University of South Florida

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):


  • Drug: modafinil
  • Other: placebo


Phase 2



   - Age ≥ 6 years and ≤ 18 years 10 months at the time of study entry (so that
   participants will be < 19 at the 6 week evaluation, which is the upper age limit for
   which the included instruments are valid).

   - Diagnosis of a primary brain tumor treated with at least one of the following:

      1. neurosurgical resection of the brain tumor;

      2. cranial irradiation; or

      3. any chemotherapy to treat the brain tumor.

   - Off-treatment and progression-free for at least 12 months and ≤ 14 years. Treatment
   cessation is defined as the final dose of chemotherapy, the last dose (fraction) of
   radiation or date of surgery, whichever occurred last.

   - Parent/Legal Guardian and child able to read English or Spanish.

   - Vision and hearing (eyeglasses and/or hearing aid permissible) sufficient for valid
   test administration and cooperation with examinations.

   - Availability of a reliable parent or legal guardian who is willing and able to
   complete all of the outcome measures and fulfill the requirements of the study,
   including administration of medications and accompanying the participant to all study

   - Females of childbearing potential must have a negative pregnancy test result and must
   agree to use a medically acceptable method of contraception throughout the entire
   study period and for 30 days after the last dose of study drug.

   - Childbearing potential is defined as girls who are >Tanner stage 2, except for those
   who have documented pan pituitary insufficiency or other hormonal state incompatible
   with pregnancy.

   - Urine pregnancy tests are acceptable.


   - Off treatment > 14 years

   - Inability to perform the testing procedure (for example, because of aphasia, motor
   deficits affecting the dominant hand, or IQ < 70)

   - Known cardiac disorders including arrhythmias, hypertension requiring treatment or
   structural heart disease

   - Diagnosis of narcolepsy, sick sinus syndrome, arrhythmia or prolonged QTc

   - History of stroke or head injury associated with loss of consciousness within 12
   months of registration

   - History of grade 2 depression or anxiety or treatment with antidepressants,
   antipsychotics or MAO inhibitors within 30 days of registration

   - Concurrent treatment with any medications or substances that are potent inhibitors or
   inducers of CYP3A4, hepatic enzyme inducing antiepileptic drugs (EIAEDs),or other
   drugs known to affect the metabolism of modafinil. Examples include but are not
   limited to itraconazole, ketoconazole, doxycycline, rifampin, St. John's wort,
   phenytoin, phenobarbital, diazepam, tricyclic antidepressants.

   - If patients were previously taking, EIAEDs, they must be off for > 2 weeks prior to
   study enrollment.

   - Treatment with other stimulant medications within 14 days of registration; however, a
   diagnosis of ADHD does NOT exclude a child from participation

   - Participants with known hypersensitivity to modafinil, armodafinil or any of its

Ages Eligible for Study

6 Years - 19 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Peds Hem/Onc CRAs
Not Recruiting